Reportlinker Adds Leading Anti-Cancer Drugs: World Market Prospects 2011-2021

NEW YORK, April 5, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Leading Anti-Cancer Drugs: World Market Prospects 2011-2021

http://www.reportlinker.com/p0470103/Leading-Anti-Cancer-Drugs-World-Market-Prospects-2011-2021.html

What will this decade hold for leading anti-cancer drugs and that therapeutic market? Our new report shows you anti-cancer drug revenue forecasts for 2011 to 2021. We provide research, data and opinions to benefit your work now.

What revenues will cancer treatment markets generate from 2011 to 2021? What gains will leading companies and products achieve? What sales trends will leading national markets - developed and developing - show?

Our study answers those questions and many others for anti-cancer agents. By ordering now, you can stay ahead. We aim to save you time and aid your decisions.

Anti-cancer drug sales exceeded $50bn worldwide in 2009, with impressive growth. Our report shows you where cancer therapies are heading from 2011 to 2021 - technology, competition and revenues. 

Over 20 million new cases of cancer are predicted in 2025, compared with 12 million in 2008 (WHO). We show the potential for cancer treatments, existing and in development. 

Our report shows you revenue forecasts at total world, sub-market, product and national levels. You can assess the potential of the anti-cancer drug industry and market now.

We show the industry's strengths, weaknesses, trends and opportunities from 2011. We show you oncology R&D trends - pipeline and emerging treatments to look out for.

In our report you can find data, analyses and opinion to benefit your research, calculations, meetings and presentations. Respond now to get that information.

Analysis and expert opinion to help your work - so you won't be left behind

Our report gives you revenue forecasts, growth rates, market shares, SWOT analysis, an R&D review and expert opinion. We include 149 tables and charts and a research interview (shown in the accompanying lists).

Delaying ordering could mean you miss out on data, opinion and trends that your competitors use to positively influence their business decisions.

Leading Anti-Cancer Drugs: World Market Prospects 2011-2021 shows you revenue trends, opportunities and challenges

Our report gives you the following advantages:

- You will receive analysis of leading anti-cancer drugs from 2009 to 2021, including predicted revenues, market shares and growth rates

- You will find revenue predictions for Avastin, MabThera, Herceptin, Glivec, Taxotere, Arimidex, Erbitux, Alimta, Revlimid and Velcade

- You will receive a forecast for the overall world cancer drugs market from 2011 to 2021

- You will receive forecasts for the main drug categories at world level - traditional antineoplastics, novel antineoplastics, hormone therapies and immunotherapies

- You will receive sales forecasts for the leading national markets from 2011 to 2021 (US, Japan, France, Germany, Italy, Spain, UK, China, Russia, India and Brazil)

- You will assess leading companies' activities and prospects in the anti-cancer drug market

- You will investigate competition and opportunities that will influence the cancer treatments industry and market from 2011 onwards

- You will see what will stimulate and restrain the industry and market

- You will review product development, assessing the potential of oncology R&D and emerging products for lung, breast, colorectal, stomach and prostate cancers

- You will investigate commercial requirements - with therapeutic needs and market opportunities discussed

- You will see discussions of personalised medicine and biosimilar drugs in cancer treatment

- You will view expert opinion from our survey, including a full interview transcript.

That mix of quantitative and qualitative market analysis sets our report apart. Our emphasis is on future revenue trends - predictions found only in our work. Our independent analysis helps you stay ahead in market knowledge. 

You can order our report, receiving the market information you need 

Our report can benefit everybody interested in cancer drug development, production, marketing and sales. We give predictions and answers you need. Please order our report now, making sure you don't miss out. 

Visiongain is a trading partner with the US Federal Government

CCR Ref number: KD4R6

NB: All visiongain reports are password locked so please let us know what licence is most suitable for your business needs

Table of Contents

1. Executive Summary

1.1 Overview of Findings

1.2 Chapter Breakdown

1.3 Research Methods

1.4 Scope of this Report

1.4.1 Drug Types Excluded from this Report

1.5 Abbreviations Used in this Report

2. Introduction: Cancer, its Physiology, Burden and Treatment

2.1 The Physiology of Cancer

2.1.1 Uncontrolled Growth

2.1.2 Dedifferentiation

2.1.3 Invasiveness and Metastasis

2.1.4 Causes of Cancer

2.2 The Incidence and Prevalence of Cancer

2.2.1 Incidence

2.2.2 Mortality

2.2.3 Survival

2.2.3.1 The Developed World

2.2.3.2 The Developing World

2.3 Treating Tumours

2.3.1 Chemotherapy

2.3.2 Traditional Antineoplastics

2.3.3 Novel Antineoplastics

2.3.3.1 Kinase Receptor Antagonists

2.3.3.2 Other Novel Antineoplastics

2.3.4 Hormone Therapies

2.3.5 Active Immunotherapy

2.3.6 Passive Immunotherapy: Monoclonal Antibodies

3. The Global Cancer Drugs Market 2011-2021

3.1 Global Cancer Drugs Market 2009

3.2 Global Cancer Drugs Market Forecast 2011-2021

3.3 Traditional Antineoplastics Market Forecast 2011-2021

3.4 Novel Antineoplastics Market Forecast 2011-2021

3.5 Hormone Therapy Market Forecast 2011-2021

3.6 Immunotherapy Market Forecast 2011-2021

4. Cancer Drugs: Leading National Market Forecasts 2011-2021

4.1 National Cancer Drug Markets 2009

4.2 The US

4.3 Japan

4.4 The EU Top Five

4.5 BRIC Countries

4.5.1 Brazil

4.5.2 Russia

4.5.3 India

4.5.4 China

5. Top 10 Cancer Drugs: Sales Forecasts 2011-2021

5.1 Market Dominated by Monoclonal Antibodies

5.2 Avastin

5.2.1 Avastin Sales 2009

5.2.2 Recent Developments

5.2.3 Avastin Sales Forecast 2011-2021

5.3 MabThera

5.3.1 MabThera Sales 2009

5.3.2 Recent Developments

5.3.3 Sales Forecast 2011-2021

5.3.4 Increased Competition

5.3.5 Biosimilar MabThera

5.4 Herceptin

5.4.1 Herceptin Sales 2009

5.4.2 Recent Developments 

5.4.3 Herceptin Sales Forecast 2011-2021

5.5 Glivec

5.5.1 Glivec Sales 2009

5.5.2 Glivec Sales Forecast 2011-2021

5.5.3 Tasigna Set to Replace Glivec

5.6 Taxotere

5.6.1 Taxotere Sales 2009

5.6.2 Patent Expiry

5.6.3 Taxotere Sales Forecast 2011-2021

5.7 Arimidex

5.7.1 Arimidex Sales 2009

5.7.2 Patent Expiry

5.8 Erbitux

5.8.1 Erbitux Sales 2009

5.8.2 Recent Developments

5.8.3 Erbitux Sales Forecast 2011-2021

5.9 Alimta

5.9.1 Alimta Sales 2009

5.9.2 Patent Disputes

5.9.3 Alimta Sales Forecast 2011-2021

5.10 Revlimid

5.10.1 Revlimid Sales 2009

5.10.2 Secondary Malignancies

5.10.3 Revlimid Sales Forecast 2011-2021

5.11 Velcade

5.11.1 Velcade Sales 2009

5.11.2 Recent Developments

5.11.3 Velcade Sales Forecast 2011-2021

6. Leading Companies in Cancer Drugs 2010

6.1 A Marketed Dominated by a Few Companies

6.2 Roche

6.2.1 Market Leader in 2009

6.2.2 Financial Performance 2010

6.2.3 Oncology Pipeline

6.2.4 Future Directions in Cancer

6.3 Novartis

6.3.1 Leading Cancer Drugs 2009

6.3.2 Financial Performance 2010

6.3.3 Oncology Pipeline

6.3.4 Future Directions in Cancer

6.4 AstraZeneca

6.4.1 Leading Cancer Drugs 2009

6.4.2 Financial Performance 2010

6.4.3 Oncology Pipeline

6.4.4 Future Directions in Cancer

6.5 Sanofi-Aventis

6.5.1 Leading Cancer Drugs 2009

6.5.2 Financial Performance 2010

6.5.3 Oncology Pipeline

6.5.4 Future Directions in Cancer

6.6 Eli Lilly

6.6.1 Leading Cancer Drugs 2009

6.6.2 Patent Issues 2010

6.6.3 Oncology Pipeline

6.6.4 Future Directions in Cancer

7. Pipeline Trends in Cancer 2011-2021

7.1 Immunotherapy: The Future of Cancer Treatment

7.1.1 Passive Immunotherapy

7.1.2 Active Immunotherapy

7.2 Lung Cancer Pipeline 2010

7.2.1 Line Extensions

7.2.2 BIBW 2992

7.2.3 MAGE-A3 ASCI

7.2.4 Talactoferrin

7.3 Breast Cancer Pipeline 2010

7.3.1 Line Extensions

7.3.2 Halaven

7.4 Colorectal Cancer Pipeline 2010

7.4.1 BAY 73-4506

7.4.2 KRX 0401

7.5 Stomach Cancer Pipeline 2010

7.5.1 Line Extensions

7.5.2 IMC1121B

7.6 Prostate Cancer Pipeline 2010

7.6.1 Provenge

7.6.2 MDV 3100

7.6.3 CB7630

7.6.4 Custirsen

8. SWOT Analysis for Cancer Drugs 2011-2021

8.1 SWOT Chart for the World Cancer Drugs Market 2011-2021

8.2 Strengths

8.2.1 High Profile Nature of Cancer

8.2.2 Off-Label Prescriptions are Common

8.2.3 Strong Drug Development Incentives

8.3 Weaknesses

8.3.1 Tumour Resistance 

8.3.2 Pricing-Out the Developing World

8.4 Opportunities

8.4.1 Rising Incidence of Cancer

8.4.1.1 Aging Populations

8.4.1.2 Smoking

8.4.1.3 Obesity

8.4.1.4 The Developing World

8.4.2 Personalised Medicine

8.4.3 Live Licensing

8.4.4 Convenient Drugs

8.5 Threats

8.5.1 The Cost-Effectiveness Debate

8.5.2 Governments are a Leading Payer for Drugs

8.5.3 Efficacy, Toxicity and Alternative Treatments

8.6 Biosimilars and Generics: Opportunity or Threat?

8.7 Personalised Medicine

8.7.1 Cancer Heterogeneity

8.7.2 Pharmacogenomics

8.7.3 Genome Screening

8.7.4 Biomarkers and Diagnostics

8.7.5 Theranostics

9. Expert Opinion

9.1 Dr Janice M. Reichert

9.1.1 Main Challenges of Monoclonal Antibodies as Cancer Therapy

9.1.2 Main Opportunities

9.1.3 Side Effects of Monoclonal Antibodies

9.1.4 Future Developments and Pipelines

9.1.5 The Effect of Biosimilars

10. Conclusions

10.1 The US Will Continue to be the World's Largest Cancer Drug Market

10.2 India and China Will be the Fastest Growing National Markets

10.3 Monoclonal Antibodies Will Dominate the Market

10.3.1 Biosimilars Have Potential in Emerging Markets

10.4 Personalised Medicine Will Become More Commonplace

10.5 Pipelines for Many Cancer Types Are Strong

10.6 Concluding Remarks

List of Tables

Table 1.1 Abbreviations Used in the Report

Table 2.1 Leading Causes of Death Worldwide, 2008-2015

Table 2.2 Ten Most Common Cancers by Incidence, 2008

Table 2.3 Ten Most Common Cancers by Mortality, 2008 & 2015

Table 2.4 Five-Year Survival Rates of Nine Cancers in the UK, 2009

Table 2.5 Categories of Oncology Drug, 2010

Table 2.6 Common Side-Effects of Traditional Antineoplastic Chemotherapy

Table 2.7 Subcategories of TANs

Table 3.1 Global Cancer Drugs Market by Category, 2009 

Table 3.2 Cancer Immunotherapy Sales, 2009

Table 3.3 Traditional Antineoplastics Sales, 2009

Table 3.4 Global Cancer Drugs Market Forecast, 2009-2021

Table 3.5 Global Cancer Drugs Market Drivers and Restraints, 2011-2021

Table 3.6 Traditional Antineoplastics Market Forecast, 2009-2021

Table 3.7 Novel Antineoplastics Market Forecast, 2009-2021

Table 3.8 Novel Antineoplastics Drivers & Restraints, 2011-2021

Table 3.9 Hormone Therapy Market Forecast, 2009-2021

Table 3.10 Hormone Therapy Drivers & Restraints, 2011-2021

Table 3.11 Immunotherapy Drivers & Restraints, 2011-2021

Table 3.12 Immunotherapy Market Forecast, 2009-2021

Table 4.1 Global Cancer Drugs Market by Region, 2009 

Table 4.2 Developed Markets Drivers and Restraints, 2011-2021

Table 4.3 Emerging Markets Drivers and Restraints, 2011-2021

Table 4.4 Global Cancer Drugs Market Forecast by Region, 2009-2021

Table 5.1 Top Ten Cancer Drugs Sales, 2009

Table 5.2 Top Ten Cancer Drugs: Key Facts, 2009 

Table 5.3 Potential New Indications for Avastin, January 2010

Table 5.4 Avastin Sales Drivers and Restraints, 2011-2021

Table 5.5 Avastin Sales Forecast, 2009-2021

Table 5.6 MabThera Sales Forecast, 2009-2021

Table 5.7 MabThera Sales Drivers and Restraints, 2011-2021

Table 5.8 Herceptin Sales, 2007-2009

Table 5.9 Herceptin Sales Forecast, 2009-2021

Table 5.10 Herceptin Sales Drivers and Restraints, 2011-2021

Table 5.11 Glivec Sales by Region, 2009 

Table 5.12 Glivec Sales Forecast, 2009-2021

Table 5.13 Glivec Sales Drivers and Restraints, 2011-2021

Table 5.14 Taxotere Approved Indications, 2010

Table 5.15 Taxotere Sales by Region, 2009 

Table 5.16 Taxotere Sales Forecast, 2009-2021

Table 5.17 Taxotere Sales Drivers and Restraints, 2011-2021

Table 5.18 Arimidex Sales by Region, 2009

Table 5.19 Arimidex Sales by Region, Q1-Q3 2010

Table 5.20 Arimidex Sales Forecast, 2009-2021

Table 5.21 Arimidex Sales Drivers and Restraints, 2011-2021

Table 5.22 Erbitux Sales by Company, 2009

Table 5.23 Erbitux Sales Drivers and Restraints, 2011-2021

Table 5.24 Erbitux Sales Forecast, 2009-2021

Table 5.25 Alimta Sales by Region, 2009

Table 5.26 Alimta Sales Forecast, 2009-2021

Table 5.27 Alimta Sales Drivers and Restraints, 2011-2021

Table 5.28 Revlimid Sales Forecast, 2009-2021

Table 5.29 Revlimid Sales Drivers and Restraints, 2011-2021

Table 5.30 Velcade Sales by Company, 2009

Table 5.31 Velcade Sales Forecast, 2009-2021

Table 5.32 Velcade Sales Drivers and Restraints, 2011-2021

Table 6.1 Cancer Drugs Market by Company, 2009 

Table 6.2 Roche Sales by Sector, 2009

Table 6.3 Roche Oncology Sales, 2009 

Table 6.4 Roche Oncology Sales, H1 2010 

Table 6.5 Roche Oncology Pipeline, November 2010

Table 6.6 Novartis Sales by Sector, 2009

Table 6.7 Novartis Oncology Sales, 2009 

Table 6.8 Novartis Oncology Sales, Q1-Q3 2010

Table 6.9 Novartis Oncology Pipeline, 2010

Table 6.10 AstraZeneca Sales by Sector, 2009 

Table 6.11 AstraZeneca Oncology Sales, 2009

Table 6.12 AstraZeneca Oncology Sales, Q1-Q3 2010

Table 6.13 AstraZeneca Oncology Pipeline, July 2010

Table 6.14 Sanofi-Aventis Sales by Sector, 2009 

Table 6.15 Sanofi-Aventis Oncology Sales by Region, 2009 

Table 6.16 Sanofi-Aventis Oncology Sales, H1 2010

Table 6.17 Sanofi-Aventis Oncology Pipeline, February 2010

Table 6.18 Eli Lilly Sales by Sector, 2009

Table 6.19 Eli Lilly Oncology Sales, 2009 

Table 6.20 Eli Lilly Oncology Pipeline, 2010

Table 7.1 Number of Drug Candidates by Indication, 2009 

Table 7.2 Abbreviations Used in Chapter 7

Table 7.3 Therapeutic Cancer Vaccines in Phase III, 2010

Table 7.4 Selected Lung Cancer Pipeline Candidates in Phase II & III, 2010

Table 7.5 Selected Breast Cancer Pipeline Candidates in Phase II & III, 2010

Table 7.6 Selected Colorectal Cancer Pipeline Candidates in Phase II & III, 2010

Table 7.7 Selected Stomach Cancer Pipeline Candidates in Phase II & III, 2010

Table 7.8 Selected Prostate Cancer Pipeline Candidates in Phase II & III, 2010

Table 8.1 SWOT Chart for the World Cancer Drugs Market, 2011-2021

Table 10.1 Global Cancer Drugs Market by Region, 2009-2021 

Table 10.2 Global Cancer Drugs Market by Drug Type, 2009-2021 

List of Figures

Figure 2.1 Leading Causes of Death Worldwide, 2008-2015

Figure 2.2 Ten Most Common Cancers by Incidence, 2008

Figure 2.3 Ten Most Common Cancers by Mortality, 2008

Figure 2.4 Ten Most Common Cancers by Mortality, 2015

Figure 2.5 Five-Year Survival Rates of Nine Cancers in the UK, 2009

Figure 3.1 Global Cancer Drugs Market by Category, 2009 

Figure 3.2 Cancer Immunotherapy Sales, 2009

Figure 3.3 Traditional Antineoplastics Sales, 2009

Figure 3.4 Global Cancer Drugs Market Forecast, 2009-2021

Figure 3.5 Traditional Antineoplastics Market Forecast, 2009-2021

Figure 3.6 Novel Antineoplastics Market Forecast, 2009-2021

Figure 3.7 Hormone Therapy Market Forecast, 2009-2021

Figure 3.8 Immunotherapy Market Forecast, 2009-2021

Figure 4.1 Global Cancer Drugs Market by Region, 2009 

Figure 4.2 Global Cancer Drugs Market by Region, 2015

Figure 4.3 Global Cancer Drugs Market by Region, 2021

Figure 4.4 US Cancer Drugs Market Forecast, 2009-2021

Figure 4.5 Japanese Cancer Drugs Market Forecast, 2009-2021

Figure 4.6 Top Five European Cancer Drugs Market Forecasts, 2009-2021

Figure 4.7 Brazilian Cancer Drugs Market Forecast, 2009-2021

Figure 4.8 Russian Cancer Drugs Market Forecast, 2009-2021

Figure 4.9 Indian Cancer Drugs Market Forecast, 2009-2021

Figure 4.10 BRIC National Cancer Drugs Markets, 2009

Figure 4.11 Chinese Cancer Drugs Market Forecast, 2009-2021

Figure 5.1 Top Ten Cancer Drugs Sales, 2009

Figure 5.2 Top Ten Cancer Drugs Sales by Drug Category, 2009 

Figure 5.3 Avastin Sales Forecast, 2009-2021

Figure 5.4 MabThera Sales Forecast, 2009-2021

Figure 5.5 Herceptin Sales, 2007-2009

Figure 5.6 Herceptin Sales Forecast, 2009-2021

Figure 5.7 Glivec Sales by Region, 2009 

Figure 5.8 Glivec Sales Forecast, 2009-2021

Figure 5.9 Taxotere Sales by Region, 2009 

Figure 5.10 Taxotere Sales Forecast, 2009-2021

Figure 5.11 Arimidex Sales by Region, 2009

Figure 5.12 Arimidex Sales by Region, Q1-Q3 2010

Figure 5.13 Arimidex Sales Forecast, 2009-2021

Figure 5.14 Erbitux Sales by Company, 2009 

Figure 5.15 Erbitux Sales Forecast, 2009-2021

Figure 5.16 Alimta Sales by Region, 2009

Figure 5.17 Alimta Sales Forecast, 2009-2021

Figure 5.18 Revlimid Sales Forecast, 2009-2021

Figure 5.19 Velcade Sales by Company, 2009 

Figure 5.20 Velcade Sales Forecast, 2009-2021

Figure 6.1 Cancer Drugs Market by Company, 2009 

Figure 6.2 Roche Sales by Sector, 2009

Figure 6.3 Roche Oncology Sales, 2009

Figure 6.4 Roche Oncology Sales, H1 2010

Figure 6.5 Novartis Sales by Sector, 2009 

Figure 6.6 Novartis Oncology Sales, 2009

Figure 6.7 Novartis Oncology Sales, Q1-Q3 2010

Figure 6.8 AstraZeneca Sales by Sector, 2009 

Figure 6.9 AstraZeneca Oncology Sales, 2009

Figure 6.10 AstraZeneca Oncology Sales, Q1-Q3 2010

Figure 6.11 Sanofi-Aventis Sales by Sector, 2009 

Figure 6.12 Sanofi-Aventis Oncology Sales, 2009

Figure 6.13 Sanofi-Aventis Oncology Sales by Region, 2009 

Figure 6.14 Sanofi-Aventis Oncology Sales, H1 2010

Figure 6.15 Eli Lilly Sales by Sector, 2009 

Figure 6.16 Eli Lilly Oncology Sales, 2009

Figure 7.1 Number of Drug Candidates by Indication, 2009 

Figure 7.2 Therapeutic Cancer Vaccines in Phase III, 2010

Companies Listed

AB Science 

Abbott Laboratories

Abraxis BioScience

Actavis

Active Biotech

Agennix

Allos Therapeutics

American Society of Clinical Oncology (ASCO)

American Society of Hematology (ASH)

Amgen

Apotex

APP Pharmaceuticals

ARIAD Pharmaceuticals

Ascenta Therapeutics

Astellas Pharma

AstraZeneca

AEterna Zentaris

Attenuon

Barr Laboratories

Bayer

Biogen Idec

Bionovo

BiPar Sciences

Boehringer Ingelheim

Bristol-Myers Squibb

Cancer Research Technology 

Cancer Research UK

Celgene

Centocor Ortho Biotech

Cipla

Concordia Pharmaceuticals

Cougar Biotechnology

CureVac

CuraGen

Cyclacel Pharmaceuticals

Cytokinetics

Daiichi Sankyo

Dako 

Dendreon

Dr. Reddy's Laboratories

Eisai

Eleison Pharmaceuticals

Eli Lilly

EMA

Endocyte

EntreMed

Exelixis

FDA

Fresenius Kabi

Genentech

Generex Biotechnology

Genmab

Genta

Genzyme

GlaxoSmithKline

GPC Biotech

Hospira

ImClone Systems

ImmunoGen

Incyte

Infinity Pharmaceuticals

Intas Biopharmaceuticals

International Cancer Genome Consortium

Introgen Therapeutics

Isis Pharmaceuticals

Johnson & Johnson

Janssen

Keryx Biopharmaceuticals

Lonza

Marshall Edwards

Medivation

Merck KGaA 

Merck Serono

Micromet

Millennium Pharmaceuticals

Mylan

National Cancer Institute (NCI) [US]

National Health Service (NHS) [UK]

National Institute for Clinical Excellence (NICE) [UK]

Nektar Therapeutics

Novartis

Novogen

OncoGenex Pharmaceuticals

Ono Pharmaceuticals

Onyx Pharmaceuticals

Oxford University

Par Pharmaceutical

Pfizer

Pharmaceutical Researchers and Manufacturers of America (PhRMA) [US]

PharmaMar USA

Pierre Fabre Pharmaceuticals

Poniard Pharmaceuticals

Princeton University

Proacta 

Proteolix

Radient Pharmaceuticals

Regeneron 

Roche

Roxane Laboratories

Sandoz

Sanofi-Aventis

Scancell

Schering-Plough

Spectrum Pharmaceuticals

Stada Arzneimittel

Sun Pharmaceuticals

Syndax Pharmaceuticals

Taiho Pharma USA

Takeda

Tapestry Pharmaceuticals

TargeGen

Teva Pharmaceutical Industries

Threshold Pharmaceuticals

TopoTarget 

Tufts University

World Health Organisation (WHO)

WILEX

Yeda Research and Development Company

Zenyaku Kogyo

To order this report:

Leading Anti-Cancer Drugs: World Market Prospects 2011-2021

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

CONTACT:  
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: +1-805-652-2626
Intl: +1-805-652-2626

SOURCE Reportlinker